MetaVia is trading at $1.20, up 5.26%, with no clear company-specific catalyst confirmed in available coverage.
- MetaVia announced Phase 1 DA-1726 data will be presented orally at the November 4 Precision Liver Symposium; this announcement does not confirm a reason for the October 29 rise.
- Available broad-market and software-sector context is negative and does not explain the upward move; trading volume or activity-level data was not provided.